
15 Sep 2021 Best Evidence Webinar: VTE prophylaxis in medical patients: is it worth it?
Dr. Aaron M Tejani is a researcher/educator/pharmacist with the Therapeutics Initiative (co-chair of the Education Working Group), a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation pharmacist with Lower Mainland Pharmacy Services (Vancouver, BC). He completed his BSc(Pharm) at UBC (Vancouver) and Doctor of Pharmacy degree at Creighton University (Omaha, Nebraska)
This webinar has already taken place. Scroll down to view a video recording of the event.
DATE: Wednesday, September 15, 2021
TIME: 12:00 – 13:00 Pacific Time PDT [UTC -7 convert to your local time]
WHERE: Delivered online using Zoom platform.
CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. You must register, attend the webinar and complete the evaluation in order to receive your certificate.
Learning Objectives
By the end of this session, participants should be able to:
- State the incidence of VTE (DVT and PE) in medical (non-surgical) inpatients
- Describe the quality of evidence for low molecular weight heparin (LMWH) when used for VTE prophylaxis
- Specify the known and unknown effects of LMWH when used for VTE prophylaxis
No Comments